Carriers of a BRCA2 variation specific to Iceland are more likely to develop aggressive and lethal prostate cancer than noncarriers, according to a study published online June 12 in the Journal of the National Cancer Institute.Mutations in the BRCA2 gene are associated with increased prostate cancer risk, but it has been unclear whether they are related to progression of the disease.
